<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04957368</url>
  </required_header>
  <id_info>
    <org_study_id>21-096</org_study_id>
    <nct_id>NCT04957368</nct_id>
  </id_info>
  <brief_title>Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial</brief_title>
  <acronym>SMILE</acronym>
  <official_title>Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karim Ladha</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unity Health Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Unity Health Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to investigate a short-term treatment option for major depressive&#xD;
      disorders by administering nitrous oxide gas. At this time, the main purpose is to complete a&#xD;
      feasibility study with 40 participants suffering from treatment-resistant depression.&#xD;
      Participants will be randomized to (1) Study group: Nitrous oxide (inhaled) + solution of&#xD;
      saline (injected) and the (2) Control group: Oxygen (inhaled) + Midazolam (injected) as an&#xD;
      Active Placebo.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recruitment rate</measure>
    <time_frame>2 Years</time_frame>
    <description>Recruitment rate</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Withdrawal rate</measure>
    <time_frame>2 Years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adherence rate</measure>
    <time_frame>2 Years</time_frame>
    <description>Feasibility</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>2 Years</time_frame>
    <description>Safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Montgomery-Åsberg Depression Rating Scale (MADRAS) Score 0-60 (Higher scores represent higher depression). Measure changes in symptoms of depression</measure>
    <time_frame>6 weeks</time_frame>
    <description>Frequencies on numbers of 1.- Remissions (defined as MADRS score &lt; 10), 2.- Responses (defined as ≥ 50% reduction in MADRS score from baseline) 3.- No Responses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toronto Side Effects Scale (TSES) - 32 items (each item has a score 1-25; higher score means higher intensity). Measure adverse side effects from antidepressant treatment</measure>
    <time_frame>6 weeks</time_frame>
    <description>Frequencies of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Treatment Resistant Depression</condition>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Nitrous Oxide + saline solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Oxygen + Midazolam</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitrous Oxide 99 %</intervention_name>
    <description>Nitrous oxide will be administered at an inspiratory concentration of 50% with concurrent intravenous saline (100ml) for one hour.</description>
    <arm_group_label>Nitrous Oxide + saline solution</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxygen + Midazolam</intervention_name>
    <description>Oxygen will be administered at 50% with intravenous midazolam (0.02mg/kg in 100ml) for one hour</description>
    <arm_group_label>Oxygen + Midazolam</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 to 65 years of age&#xD;
&#xD;
          2. Meeting Diagnostic and Statistical Manual for Mental Disorders (DSM-5) criteria for&#xD;
             Major Depressive Disorder (MDD)&#xD;
&#xD;
          3. Current major depressive episode as confirmed by the Mini International&#xD;
             Neuropsychiatric Interview (MINI) for DSM-5&#xD;
&#xD;
          4. Experiencing moderate to severe depressive episode, as defined by the Hamilton&#xD;
             Depression Rating Scale (HAMD)&gt;17&#xD;
&#xD;
          5. Failure of two trials of antidepressant therapy of adequate dose and duration, during&#xD;
             the current depressive episode&#xD;
&#xD;
          6. For women of childbearing potential, use of highly effective or double-barrier methods&#xD;
             of contraception. Abstinence is acceptable if it is the preferred and usual lifestyle&#xD;
             of the female participant&#xD;
&#xD;
          7. Capacity to provide informed consent.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          1. Acute suicidality defined as score ≥3 on HAMD item 3&#xD;
&#xD;
          2. Major Depressive Episode in people with Bipolar Disorder&#xD;
&#xD;
          3. Current substance abuse or dependence and/or history of alcohol abuse or dependence&#xD;
             within the past year&#xD;
&#xD;
          4. Dementia&#xD;
&#xD;
          5. Current or lifetime history of schizophrenia or schizoaffective disorder&#xD;
&#xD;
          6. Current history of dissociative disorders&#xD;
&#xD;
          7. Known history of hypersensitivity or allergy to Nitrous Oxide, Midazolam or any&#xD;
             ingredients in the study formulations&#xD;
&#xD;
          8. Contraindication to receiving nitrous oxide&#xD;
&#xD;
          9. Chronic cobalamin or folate deficiency&#xD;
&#xD;
         10. Contraindication to receiving the placebo midazolam&#xD;
&#xD;
         11. Use of centrally acting medicinal products, such as opioid agonists, morphine&#xD;
             derivatives, benzodiazepines and/or other central nervous system depressants such as&#xD;
             barbiturates and alcohol&#xD;
&#xD;
         12. Pregnancy or breastfeeding in female participants&#xD;
&#xD;
         13. Electroconvulsive therapy within the current depressive episode&#xD;
&#xD;
         14. Receiving ketamine treatment within the current depressive episode&#xD;
&#xD;
         15. Unwilling to maintain current antidepressant regimen.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Karim Ladha, MD</last_name>
    <phone>416-864-5825</phone>
    <email>karim.ladha@mail.utoronto.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Janneth Pazmino-Canizares, MSc</last_name>
    <phone>416-864-6060</phone>
    <phone_ext>49561</phone_ext>
    <email>Janneth.Pazmino-Canizares@unityhealth.to</email>
  </overall_contact_backup>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2021</study_first_posted>
  <last_update_submitted>September 27, 2021</last_update_submitted>
  <last_update_submitted_qc>September 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Unity Health Toronto</investigator_affiliation>
    <investigator_full_name>Karim Ladha</investigator_full_name>
    <investigator_title>Associate Scientist, Staff Physician</investigator_title>
  </responsible_party>
  <keyword>Feasibility trial</keyword>
  <keyword>Nitrous Oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
    <mesh_term>Depressive Disorder, Treatment-Resistant</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Nitrous Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No individual participant data has been planned to be shared with other researchers at this point since this is a feasibility study with only 40 participants</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

